Drugs / HepaCure
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05989958 | Sep 2023 → Sep 2026 overdue | hepatitis, liver failure | Hexaell Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HepaCure | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05989958 ↗ |
| Modality | Cell therapy | “hiHep cell-based bio-artificial liver support system (HepaCure)” NCT05989958 ↗ |
| Route | Other | “HepaCure will be administered in extracorporal dialysis following the treatment of DPMAS and LPE.” NCT05989958 ↗ |